Gao F, et al. - Researchers examined whether pregnant women with hepatitis B virus (HBV) could achieve higher benefits with initiating tenofovir disoproxil fumarate (TDF) treatment in the second trimester vs the third trimester. They enrolled 35-year-old pregnant women with HBV DNA > 2×10⁶ IU/mL and divided them into two subgroups: the second-trimester group who initiated TDF treatment at 24–27 weeks and the third-trimester group who initiated TDF treatment at 28–30 weeks. The second-trimester group comprised 80 pregnant women and the third-trimester group comprised 49 pregnant women. The analysis revealed the achievement of better viral suppression in highly viraemic pregnant women in correlation to initiating TDF treatment from the second trimester than initiating TDF treatment from the third trimester without increasing additional adverse reactions. They recommend frequent monitoring HB level during treatment to avoid anemia.